This report describes and explains the ulcerative colitis market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global ulcerative colitis market reached a value of nearly $19.89 billion in 2025, having grown at a compound annual growth rate (CAGR) of 6.7% since 2020. The market is expected to grow from $19.89 billion in 2025 to $26.3 billion in 2030 at a rate of 5.7%. The market is then expected to grow at a CAGR of 5% from 230 and reach $33.61 billion in 2035.
Growth in the historic period resulted from rising increasing prevalence of inflammatory bowel disease (IBD), increased focus on mucosal healing, increasing adoption of biologic and targeted therapies and increasing investments in pharmaceutical research and development. Factors that negatively affected growth in the historic period were limited access to specialty care and high biologic treatment costs.
Going forward, increased R&D investments on gut health, increasing use of combination therapy, increasing pharmaceutical investments in immune-mediated inflammatory diseases (IMID) and increasing incidence of immune dysregulation disorders will drive growth. Factors that could hinder the growth of the ulcerative colitis market in the future include supply chain disruptions, safety and side-effect concerns and impact of trade war and tariff.
The ulcerative colitis market is segmented by drug class into 5-aminocalicylic acid (5-ASA), steroid (corticosteroids) and biopharmaceuticals. The biopharmaceuticals market was the largest segment of the ulcerative colitis market segmented by drug class, accounting for 45.9% or $9.13 billion of the total in 2025. Going forward, the biopharmaceuticals segment is expected to be the fastest growing segment in the ulcerative colitis market segmented by drug class, at a CAGR of 7.5% during 2025-2030.
The ulcerative colitis market is segmented by drug type into brand drugs and generic drugs. The brand drugs market was the largest segment of the ulcerative colitis market segmented by drug type, accounting for 74.6% or $14.84 billion of the total in 2025. Going forward, the generic drugs segment is expected to be the fastest growing segment in the ulcerative colitis market segmented by drug type, at a CAGR of 8.3% during 2025-2030.
The ulcerative colitis market is segmented by disease type into ulcerative proctitis, left-sided colitis, and pancolitis or universal colitis. The pancolitis or universal colitis market was the largest segment of the ulcerative colitis market segmented by disease type, accounting for 59.4% or $11.81 billion of the total in 2025. Going forward, the pancolitis or universal colitis segment is expected to be the fastest growing segment in the ulcerative colitis market segmented by disease type, at a CAGR of 7% during 2025-2030.
The ulcerative colitis market is segmented by molecule type into biologics and small molecules. The small molecules market was the largest segment of the ulcerative colitis market segmented by molecule type, accounting for 68.6% or $13.64 billion of the total in 2025. Going forward, the small molecules segment is expected to be the fastest growing segment in the ulcerative colitis market segmented by molecule type, at a CAGR of 6.3% during 2025-2030.
The ulcerative colitis market is segmented by route of administration into oral, parenteral and foams. The parenteral market was the largest segment of the ulcerative colitis market segmented by route of administration, accounting for 72.9% or $14.5 billion of the total in 2025. Going forward, the oral segment is expected to be the fastest growing segment in the ulcerative colitis market segmented by route of administration, at a CAGR of 6.5% during 2025-2030.
The ulcerative colitis market is segmented by end-user into hospital pharmacies, retail pharmacies, drug store and other end-user. The hospital pharmacies market was the largest segment of the ulcerative colitis market segmented by end-user, accounting for 41.4% or $8.23 billion of the total in 2025. Going forward, the other end-user segment is expected to be the fastest growing segment in the ulcerative colitis market segmented by end-user, at a CAGR of 10.6% during 2025-2030.
North America was the largest region in the ulcerative colitis market, accounting for 41.8% or $8.31 billion of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the ulcerative colitis market will be Asia Pacific and Middle East where growth will be at CAGRs of 7.7% and 7% respectively. These will be followed by South America and Eastern Europe where the markets are expected to grow at CAGRs of 6.6% and 5.9% respectively.
The global ulcerative colitis market is concentrated, with large players operating in the market. The top 10 competitors in the market made up 40.43% of the total market in 2024. Johnson & Johnson was the largest competitor with a 16.43% share of the market, followed by AbbVie Inc. with 8.52%, Pfizer Inc. with 6.25%, Takeda Pharmaceutical Company Limited, with 4.85%, Ferring Pharmaceuticals, with 1.98%, Celltrion Inc. (Celltrion Healthcare Co., Ltd) with 0.71%, Sun Pharmaceutical Industries with 0.66%, Sandoz Group with 0.62%, Bristol Myers Squibb (BMS) Company with 0.24% and Biogen Inc. with 0.18%.
The top opportunities in the ulcerative colitis market segmented by drug class will arise in the biopharmaceuticals segment, which will gain $3.98 billion of global annual sales by 2030. The top opportunities in the ulcerative colitis market segmented by drug type will arise in the offline segment, which will gain $3.93 billion of global annual sales by 2030. The top opportunities in the ulcerative colitis market segmented by disease type will arise in the pancolitis or universal colitis segment, which will gain $4.78 billion of global annual sales by 2030. The top opportunities in the ulcerative colitis market segmented by molecule type will arise in the small molecule segment, which will gain $4.91 billion of global annual sales by 2030. The top opportunities in the ulcerative colitis market segmented by route of administration will arise in the parenteral segment, which will gain $4.51 billion of global annual sales by 2030. The top opportunities in the ulcerative colitis market segmented by end-user will arise in the other end-user segment, which will gain $2.29 billion of global annual sales by 2030. The ulcerative colitis market size will gain the most in the USA at $1.93 billion.
Market-trend-based strategies for the ulcerative colitis market include new liquid formulation of infliximab reduces preparation time and costs, shift toward shared decision-making in IBD care, expansion of novel non-TNF targeted therapies to broaden treatment options, focus on early detection and personalized treatment pathways through precision medicine and expansion of anti-TNF biosimilars to improve cost-effectiveness and access.
Player-adopted strategies in the ulcerative colitis market include focus on strengthening their business expertise through new approvals.
To take advantage of the opportunities, the analyst recommends the ulcerative colitis companies to focus on integrated, cost-efficient automotive electronics platforms, focus on collaborative development aligned with OEM and end-user needs, focus on diversified, targeted automotive electronics portfolios, focus on data-driven, early-stage automotive electronics solutions, focus on scalable, cost-efficient automotive electronics platforms, focus on portfolio expansion aligned with high-growth therapeutic shifts, focus on dual-tier product strategies that balance premium value and scale, focus on extent-specific treatment strategies with priority on severe disease, focus on oral small molecules while sustaining biologic leadership, focus on delivery-route optimization across disease severity, focus on integrated distribution expansion across care settings, focus on value-based and tiered pricing discipline, focus on evidence-led clinical promotion with clear outcomes, focus on patient-centered promotion that improves engagement and adherence, focus on channel-specific distribution strategies with hospital leadership.
This product will be delivered within 3-5 business days.
The global ulcerative colitis market reached a value of nearly $19.89 billion in 2025, having grown at a compound annual growth rate (CAGR) of 6.7% since 2020. The market is expected to grow from $19.89 billion in 2025 to $26.3 billion in 2030 at a rate of 5.7%. The market is then expected to grow at a CAGR of 5% from 230 and reach $33.61 billion in 2035.
Growth in the historic period resulted from rising increasing prevalence of inflammatory bowel disease (IBD), increased focus on mucosal healing, increasing adoption of biologic and targeted therapies and increasing investments in pharmaceutical research and development. Factors that negatively affected growth in the historic period were limited access to specialty care and high biologic treatment costs.
Going forward, increased R&D investments on gut health, increasing use of combination therapy, increasing pharmaceutical investments in immune-mediated inflammatory diseases (IMID) and increasing incidence of immune dysregulation disorders will drive growth. Factors that could hinder the growth of the ulcerative colitis market in the future include supply chain disruptions, safety and side-effect concerns and impact of trade war and tariff.
The ulcerative colitis market is segmented by drug class into 5-aminocalicylic acid (5-ASA), steroid (corticosteroids) and biopharmaceuticals. The biopharmaceuticals market was the largest segment of the ulcerative colitis market segmented by drug class, accounting for 45.9% or $9.13 billion of the total in 2025. Going forward, the biopharmaceuticals segment is expected to be the fastest growing segment in the ulcerative colitis market segmented by drug class, at a CAGR of 7.5% during 2025-2030.
The ulcerative colitis market is segmented by drug type into brand drugs and generic drugs. The brand drugs market was the largest segment of the ulcerative colitis market segmented by drug type, accounting for 74.6% or $14.84 billion of the total in 2025. Going forward, the generic drugs segment is expected to be the fastest growing segment in the ulcerative colitis market segmented by drug type, at a CAGR of 8.3% during 2025-2030.
The ulcerative colitis market is segmented by disease type into ulcerative proctitis, left-sided colitis, and pancolitis or universal colitis. The pancolitis or universal colitis market was the largest segment of the ulcerative colitis market segmented by disease type, accounting for 59.4% or $11.81 billion of the total in 2025. Going forward, the pancolitis or universal colitis segment is expected to be the fastest growing segment in the ulcerative colitis market segmented by disease type, at a CAGR of 7% during 2025-2030.
The ulcerative colitis market is segmented by molecule type into biologics and small molecules. The small molecules market was the largest segment of the ulcerative colitis market segmented by molecule type, accounting for 68.6% or $13.64 billion of the total in 2025. Going forward, the small molecules segment is expected to be the fastest growing segment in the ulcerative colitis market segmented by molecule type, at a CAGR of 6.3% during 2025-2030.
The ulcerative colitis market is segmented by route of administration into oral, parenteral and foams. The parenteral market was the largest segment of the ulcerative colitis market segmented by route of administration, accounting for 72.9% or $14.5 billion of the total in 2025. Going forward, the oral segment is expected to be the fastest growing segment in the ulcerative colitis market segmented by route of administration, at a CAGR of 6.5% during 2025-2030.
The ulcerative colitis market is segmented by end-user into hospital pharmacies, retail pharmacies, drug store and other end-user. The hospital pharmacies market was the largest segment of the ulcerative colitis market segmented by end-user, accounting for 41.4% or $8.23 billion of the total in 2025. Going forward, the other end-user segment is expected to be the fastest growing segment in the ulcerative colitis market segmented by end-user, at a CAGR of 10.6% during 2025-2030.
North America was the largest region in the ulcerative colitis market, accounting for 41.8% or $8.31 billion of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the ulcerative colitis market will be Asia Pacific and Middle East where growth will be at CAGRs of 7.7% and 7% respectively. These will be followed by South America and Eastern Europe where the markets are expected to grow at CAGRs of 6.6% and 5.9% respectively.
The global ulcerative colitis market is concentrated, with large players operating in the market. The top 10 competitors in the market made up 40.43% of the total market in 2024. Johnson & Johnson was the largest competitor with a 16.43% share of the market, followed by AbbVie Inc. with 8.52%, Pfizer Inc. with 6.25%, Takeda Pharmaceutical Company Limited, with 4.85%, Ferring Pharmaceuticals, with 1.98%, Celltrion Inc. (Celltrion Healthcare Co., Ltd) with 0.71%, Sun Pharmaceutical Industries with 0.66%, Sandoz Group with 0.62%, Bristol Myers Squibb (BMS) Company with 0.24% and Biogen Inc. with 0.18%.
The top opportunities in the ulcerative colitis market segmented by drug class will arise in the biopharmaceuticals segment, which will gain $3.98 billion of global annual sales by 2030. The top opportunities in the ulcerative colitis market segmented by drug type will arise in the offline segment, which will gain $3.93 billion of global annual sales by 2030. The top opportunities in the ulcerative colitis market segmented by disease type will arise in the pancolitis or universal colitis segment, which will gain $4.78 billion of global annual sales by 2030. The top opportunities in the ulcerative colitis market segmented by molecule type will arise in the small molecule segment, which will gain $4.91 billion of global annual sales by 2030. The top opportunities in the ulcerative colitis market segmented by route of administration will arise in the parenteral segment, which will gain $4.51 billion of global annual sales by 2030. The top opportunities in the ulcerative colitis market segmented by end-user will arise in the other end-user segment, which will gain $2.29 billion of global annual sales by 2030. The ulcerative colitis market size will gain the most in the USA at $1.93 billion.
Market-trend-based strategies for the ulcerative colitis market include new liquid formulation of infliximab reduces preparation time and costs, shift toward shared decision-making in IBD care, expansion of novel non-TNF targeted therapies to broaden treatment options, focus on early detection and personalized treatment pathways through precision medicine and expansion of anti-TNF biosimilars to improve cost-effectiveness and access.
Player-adopted strategies in the ulcerative colitis market include focus on strengthening their business expertise through new approvals.
To take advantage of the opportunities, the analyst recommends the ulcerative colitis companies to focus on integrated, cost-efficient automotive electronics platforms, focus on collaborative development aligned with OEM and end-user needs, focus on diversified, targeted automotive electronics portfolios, focus on data-driven, early-stage automotive electronics solutions, focus on scalable, cost-efficient automotive electronics platforms, focus on portfolio expansion aligned with high-growth therapeutic shifts, focus on dual-tier product strategies that balance premium value and scale, focus on extent-specific treatment strategies with priority on severe disease, focus on oral small molecules while sustaining biologic leadership, focus on delivery-route optimization across disease severity, focus on integrated distribution expansion across care settings, focus on value-based and tiered pricing discipline, focus on evidence-led clinical promotion with clear outcomes, focus on patient-centered promotion that improves engagement and adherence, focus on channel-specific distribution strategies with hospital leadership.
This product will be delivered within 3-5 business days.
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Global Ulcerative Colitis Growth Analysis and Strategic Analysis Framework
9 Global Ulcerative Colitis Market Segmentation
10 Ulcerative Colitis Market, Regional and Country Analysis
11 Asia-Pacific Market
12 Western Europe Market
13 Eastern Europe Market
14 North America Market
15 South America Market
16 Middle East Market
17 Africa Market
18 Competitive Landscape and Company Profiles
19 Other Major and Innovative Companies
24 Key Mergers and Acquisitions
25 Recent Developments in Ulcerative Colitis
26 Opportunities and Strategies
28 Ulcerative Colitis Market, Conclusions and Recommendations
29 Appendix
Executive Summary
Ulcerative Colitis Global Market Opportunities and Strategies to 2035 provides the strategists; marketers and senior management with the critical information they need to assess the global ulcerative colitis market as it emerges from the COVID-19 shut down.Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for ulcerative colitis? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The ulcerative colitis market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider ulcerative colitis market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by drug class, by drug type, by disease type, by molecule type, by route of administration, and by end-user.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis and Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Global Market Size and Growth Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional and Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by drug class, by drug type, by disease type, by molecule type, by route of administration, and by end-user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major and Innovative Companies Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Recent Developments Information on recent developments in the market covered in the report.
- Market Opportunities and Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions and Recommendations - This section includes recommendations for ulcerative colitis providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
1) By Drug Class: 5-Aminocalicylic Acid (5-ASA); Steroid (Corticosteroids); Biopharmaceuticals
2) By Drug Type: Brand Drugs; Generic Drugs
3) By Disease Type: Ulcerative Proctitis; Left-Sided Colitis; Pancolitis Or Universal Colitis
4) By Molecule Type: Biologics; Small Molecules
5) By Route Of Administration: Oral; Parenteral; Foams
6) By End-User: Hospital Pharmacies; Retail Pharmacies; Drug Store; Other End-User
Companies Mentioned: Johnson & Johnson; AbbVie Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; Ferring Pharmaceuticals
Countries: China; India; USA; South Korea; Japan; Brazil; Indonesia; Germany; UK; Russia; France; Italy; Canada; Spain; Australia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; ulcerative colitis indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- Johnson & Johnson
- AbbVie Inc.
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Ferring Pharmaceuticals
- Celltrion Inc. (Celltrion Healthcare Co., Ltd)
- Sun Pharmaceutical Industries
- Sandoz Group
- Bristol Myers Squibb (BMS) Company
- Biogen Inc.
- Novartis
- Abbott Laboratories
- Eli Lilly and Company
- Amgen Inc.
- Astellas Pharma
- Dr. Reddy's Laboratories Ltd.
- Cipla Limited
- Mallinckrodt Pharmaceuticals
- Merck Group
- Zydus Lifesciences Limited
- Immuron Limited
- Anatara Lifesciences
- EA Pharma Co., Ltd.
- Eisai Co., Ltd.
- Sinopharm Group
- Ajinomoto Pharmaceuticals
- Mochida Pharmaceutical Co., Ltd.
- Salix Pharmaceuticals
- Mitsubishi Tanabe Pharma Corporation
- Bausch Health
- UCB
- Boehringer Ingelheim
- Everest Medicines
- Dr. Falk Pharma International
- Chugai Pharmaceutical
- Biocon Limited
- SGS S.A.
- EnteroBiotix
- Navamedic AB
- F. Hoffmann-La Roche AG
- Grünenthal GmbH
- Kelso Pharma
- GlaxoSmithKline plc
- Bayer AG
- Sanofi S.A.
- Dr. Pfleger
- Ipsen
- Biofarma Group
- Streuli Pharma
- Kruidvat
- Omega Pharma
- Almirall
- Faes Farma
- Angelini Pharma
- Menarini
- Bial
- Daiichi Sankyo
- HiDoc Technologies GmbH
- Tillotts Pharma AG
- Cosmo Pharmaceuticals NV
- Pharmidex
- Intract Pharma Limited
- Prometheus Laboratories
- BioLineRx Ltd.
- InDex Pharmaceuticals AB
- RedHill Biopharma Ltd.
- Renexxion Ireland Limited
- Arena Pharmaceuticals Ltd.
- Alvotech SA
- Microbiotica
- Advanz Pharma
- Abivax
- Sterna Biologicals GmbH
- Teva Pharmaceutical Company
- Polpharma Biologics
- Formycon
- Biocad
- JAMP Pharma Group
- Pendopharm
- Pharmascience Inc.
- Viatris Canada
- Gilead Sciences Inc.
- Celltrion USA Inc.
- Janssen
- Zydus Pharmaceuticals
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 524 |
| Published | May 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 19.89 Billion |
| Forecasted Market Value ( USD | $ 33.61 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 85 |
